Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | GSK3B | P49841 | 7/20 | 0.47 |
| ▸ | ATR | Q13535 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953665 | 1.00 | MAPT (0.47) | MAPTGSK3BATRUSP2ABL1 | |
| SCHEMBL951966 | 0.90 | GPR6 (0.51) | MAPTUSP2ABL1TSHRRIN1 | |
| SCHEMBL951968 | 0.90 | GPR6 (0.51) | MAPTUSP2ABL1TSHRRIN1 | |
| SCHEMBL951730 | 0.89 | EBP (0.43) | USP2ABL1TSHRRIN1SMN1; SMN2 | |
| SCHEMBL951728 | 0.89 | EBP (0.43) | USP2ABL1TSHRRIN1SMN1; SMN2 | |
| SCHEMBL953898 | 0.88 | SMN1; SMN2 (0.46) | MAPTSMN1; SMN2EBPSIGMAR1DRD2 | |
| SCHEMBL953897 | 0.88 | SMN1; SMN2 (0.46) | MAPTSMN1; SMN2EBPSIGMAR1DRD2 | |
| SCHEMBL954119 | 0.88 | EBP (0.42) | USP2SMN1; SMN2GPR6EBPSIGMAR1 | |
| SCHEMBL954120 | 0.88 | EBP (0.42) | USP2SMN1; SMN2GPR6EBPSIGMAR1 | |
| SCHEMBL955063 | 0.86 | CHRM1 (0.42) | SMN1; SMN2GPR6EBPSIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796274-B2 | Piperazine derivatives and their use in controlling pests | SYNGENTA CROP PROTECTION LLC (US) | 2014-08-05 | — | — | US | disclosed |
| EP-1755396-B1 | PIPERAZIN DERIVATIVES AND THEIR USE IN CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20110003991-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN CONTROLLING PESTS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807679-B2 | 2-chloro-N-(4-chloro-2-{4-[(E)-3-(4-chloro-phenyl)-allyl]-piperazin-1-yl}-phenyl)-isonicotinamide; for insects, acarines, nematodes and molluscs | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080076777-A1 | 2-chloro-N-(4-chloro-2-{4-[(E)-3-(4-chloro-phenyl)-allyl]-piperazin-1-yl}-phenyl)-isonicotinamide; for insects, acarines, nematodes and molluscs | SYNGENTA CROP PROTECTION, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003991-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN CONTROLLING PESTS | CHRM1, CHRM5, PRMT5 | MAPT 4018/4885GSK3B 4733/4885ATR 863/4885 |
| US-20080076777-A1 | 2-chloro-N-(4-chloro-2-{4-[(E)-3-(4-chloro-phenyl)-allyl]-piperazin-1-yl}-phenyl)-isonicotinamide; for insects, acarines, nematodes and molluscs | CHRM1, CHRM2, CHRM5 | MAPT 2047/4885GSK3B 4764/4885ATR 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.